Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases.
Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria.
The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome.
Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 20 | -0.44 Increased by +48.24% | -0.52 Increased by +15.38% |
| Jul 30, 20 | -0.58 Increased by +36.96% | -0.56 Decreased by -3.57% |
| May 11, 20 | 0.02 Increased by +102.02% | -0.67 Increased by +102.99% |
| Feb 24, 20 | -0.70 Decreased by -288.89% | -0.64 Decreased by -9.37% |
| Oct 30, 19 | -0.85 Increased by +36.57% | -1.05 Increased by +19.05% |
| Aug 6, 19 | -0.92 Decreased by -64.29% | -0.64 Decreased by -43.75% |
| May 7, 19 | -0.99 Decreased by -115.22% | -0.57 Decreased by -73.68% |
| Feb 26, 19 | -0.18 Increased by +60.00% | -0.48 Increased by +62.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 20 | 51.14 M Increased by +15.25% | -22.55 M Increased by +38.20% | Decreased by -44.09% Increased by +46.38% |
| Jun 30, 20 | 48.43 M Increased by +8.33% | -26.07 M Increased by +32.64% | Decreased by -53.83% Increased by +37.82% |
| Mar 31, 20 | 47.77 M Increased by +20.72% | 808.00 K Increased by +101.97% | Increased by +1.69% Increased by +101.63% |
| Dec 31, 19 | 46.69 M Increased by +6.66% | -30.26 M Decreased by -305.89% | Decreased by -64.81% Decreased by -280.53% |
| Sep 30, 19 | 44.37 M Increased by +9.01% | -36.49 M Increased by +33.07% | Decreased by -82.23% Increased by +38.60% |
| Jun 30, 19 | 44.71 M Increased by +8.15% | -38.70 M Decreased by -73.32% | Decreased by -86.57% Decreased by -60.26% |
| Mar 31, 19 | 39.57 M Increased by +2.96% | -40.98 M Decreased by -122.97% | Decreased by -103.56% Decreased by -116.56% |
| Dec 31, 18 | 43.77 M Increased by +3.78% | -7.46 M Increased by +57.69% | Decreased by -17.03% Increased by +59.23% |